Recombinant COVID-19 variant vaccine (Sf9 cell)

BIOLOGICAL3 trials

Sponsors

WestVac Biopharma Co., Ltd.

Conditions

COVID-19SARS-CoV-2 Infection

Phase 2

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

WithdrawnNCT05465902

WestVac Biopharma Co., Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2023-07-07End: 2024-12-31Updated: 2025-03-28

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

CompletedNCT05770180

WestVac Biopharma Co., Ltd.COVID-19

Start: 2023-03-30End: 2024-04-09Updated: 2024-07-24

Phase 3

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

WestVac Biopharma Co., Ltd.COVID-19

Start: 2023-12-19End: 2025-01-31Target: 4800Updated: 2024-04-23